EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study

Mauro Silingardi iD, Fulvia Zappulo iD, Ada Dormi, Attilia Maria Pizzini, Chiara Donadei iD, Maria Cappuccilli, Chiara Fantoni, Stefania Zaccaroni, Valeria Pizzuti iD, Nicola Cilloni, Simona Tantillo, Antonella Guidi und 3 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115395 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mauro Silingardi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy. Hauptthemen laut MEDLINE: COVID-19, Thrombotic Microangiopathies, Blood Coagulation Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Siemens, Thermofisher, Werfen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe COVID-19 is often associated with coagulopathy and thrombotic complications. The underlying mechanisms are complex and multifactorial, involving platelet activation, dysregulation of the complement cascade, fibrinolytic imbalance, release of pro-inflammatory cytokines, immunothrombosis, antiphospholipid antibodies, and alterations in the von Willebrand factor (vWF)/ADAMTS13 axis. These pathways are also implicated in thrombotic microangiopathies (TMAs), characterized by endothelial injury and widespread microvascular thrombosis. In this prospective monocentric observational study, we investigated whether COVID-19-associated coagulopathy meets the criteria for TMA and evaluated the roles of complement activation and vWF/ADAMTS13 imbalance in disease severity. Forty-three hospitalized COVID-19 patients were enrolled and stratified by disease severity. Blood samples collected at admission were analyzed for hematologic, coagulation, inflammatory, and complement parameters. A 30-day follow-up recorded survival and thrombotic events. All patients showed elevated vWF and factor VIII levels; however, only vWF collagen-binding activity (vWF-CBA) significantly correlated with disease severity. ADAMTS13 activity remained above 60% in all cases, and no schistocytes were detected, arguing against a diagnosis of classical TMA. Nevertheless, the vWF-CBA/ADAMTS13 ratio was significantly higher in severe cases, particularly in unvaccinated individuals, suggesting endothelial dysregulation. Complement analysis revealed increased C5a levels and decreased C3b/iC3b ratios in severe disease, consistent with complement activation and consumption. C2 levels were also lower in these patients. Although complement activation and vWF/ADAMTS13 imbalance did not directly correlate, both pathways showed a similar trend according to disease severity. Overall, our findings indicate that COVID-19-related coagulopathy does not fulfill the criteria for classical TMA but shows features of complement-mediated endothelial injury and vWF dysregulation. The vWF-CBA may serve as a rapid, standardized tool for assessing endothelial dysfunction. Activation of the complement system, particularly via the lectin and alternative pathways, appears central to the prothrombotic state in severe COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Thrombotic MicroangiopathiesBlood Coagulation DisordersHumansMaleFemaleMiddle AgedProspective Studiesvon Willebrand FactorADAMTS13 ProteinAgedSARS-CoV-2AdultSeverity of Illness IndexComplement Activation

Stichwörter der Autor:innen

ADAMTS13COVID-19-associated coagulopathycomplement activationinflammatory cytokinesvon Willebrand factor

Substanzen

von Willebrand FactorADAMTS13 ProteinADAMTS13 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
  • Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Biostatistics, Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy.
  • Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi", 40133 Bologna, Italy.
  • Laboratorio Unico Metropolitano, AUSL Bologna, 40133 Bologna, Italy.

ORCID-Profile: Mauro Silingardi, Fulvia Zappulo, Chiara Donadei, Valeria Pizzuti, Gaetano La Manna, Giorgia Comai

Förderung

  • Siemens
  • Thermofisher
  • Werfen
  • Siemens Healthcare
  • ThermoFisher Scientific
  • Wefern

Zitieren

APA

Silingardi, M., Zappulo, F., Dormi, A., Pizzini, A. M., Donadei, C., Cappuccilli, M., Fantoni, C., Zaccaroni, S., Pizzuti, V., Cilloni, N., Tantillo, S., Guidi, A., Mancini, R., La Manna, G., & Comai, G. (2025). Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115395

Vancouver

Silingardi M, Zappulo F, Dormi A, Pizzini AM, Donadei C, Cappuccilli M, et al. Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115395

BibTeX
@article{Silingardi2025,
  author = {Silingardi, Mauro and Zappulo, Fulvia and Dormi, Ada and Pizzini, Attilia Maria and Donadei, Chiara and Cappuccilli, Maria and Fantoni, Chiara and Zaccaroni, Stefania and Pizzuti, Valeria and Cilloni, Nicola and Tantillo, Simona and Guidi, Antonella and Mancini, Rita and La Manna, Gaetano and Comai, Giorgia},
  title = {Is COVID-19 Coagulopathy a Thrombotic Microangiopathy? A Prospective, Observational Study},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115395}
}
Kostenlos starten →